Navigation Links
Calando Pharmaceuticals Announces Preclinical Efficacy and Safety,Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

Data Indicate Significant Anti-Tumor Effects of Targeted, Systemic siRNA Therapeutic at Doses Significantly Lower Than the Limits of Safe Administrations in Rodent and Non-Human Primates

PASADENA, Calif., April 16, 2007 /PRNewswire/ -- Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation presented positive results of preclinical efficacy testing in mice using multiple, systemic dosing with Calando's lead siRNA therapeutic candidate CALAA-01, a nanoparticle containing non-chemically modified siRNA and a transferrin protein targeting agent at the American Association for Cancer Research (AACR) annual meeting on April 17, 2007 in Los Angeles, California.

The presentation is entitled "Development and in vivo tolerability and efficacy testing of a therapeutic formulation containing siRNA against the M2 subunit of ribonucleotide reductase in mice and monkeys." Calando's presentation details the results of a pilot safety study of Calando's lead siRNA-containing nanoparticle formulation CALAA-01 in rodents and monkeys. Additionally, data from a multi-dose efficacy study in mice using systemically-administered siRNA nanoparticles showed significant anti-tumor activity at dose levels that are significantly below the upper limits of safe, systemic, multi-dose administrations in both rodents and monkeys.

"Based on this data, we are very optimistic as we move closer to an IND filing later this year." said John Petrovich, Calando's CEO. "This data combined with other recently announced data shows efficacy as well as an overall lack of toxicity using CALAA-01."

The formulation investigated contains Calando's proprietary delivery technology and utilizes RNA interference in cancer cells with an siRNA duplex targeting the M2 subunit of ribonucleotide reductase, a well-established cancer target. This duplex, developed at Calando, demon
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
5. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/25/2008)...e recovery , , Audio and Web Video Resource...o Clinic News Blog. Please see the bottom of this ...nn., Nov. 25 A Mayo Cli...t think they,re having a stroke -- and as a result...worsens. The findings appear in the current issue ...
(Date:11/25/2008)... Nov. 25 Proteolix, Inc., a,leade...eutics that target,protein degradation pathways i... that data from two ongoing Phase 2 clinical trial...ented at the upcoming 50th Annual Meeting of the,... is the first in a new class,of specific proteaso...
(Date:11/25/2008)...nical Trial to Assess Survival of Patients Receivi...sectable Hepatocellular Carcinoma , , BELLE... Oncology, Inc. (LSO) today announced the completi...l of Light Infusion Therapy(TM) (Litx(TM)) as a tr...(HCC), also known as hepatoma or primary liver can...
(Date:11/24/2008)...RNewswire/ -- Domino,s Pizza (NYSE: DPZ ), the,...ing up to raise dough for,the kids of St. Jude Ch...,Thanks and Giving campaign. Domino,s customers w...int of purchase to benefit the children of St. Jud...hone or when ordering online at, www.dominos.com ...
Breaking Medicine Technology:Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 1July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 2July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 4Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 1Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 2Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 1Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 2Two New Jersey Hormone Therapy Lawsuits Dismissed 6534 1
...O VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AV... the presentation of,Phase III data, including eff... outcomes in patients with diabetic peripheral,neu...al drug,Zenvia(TM) (dextromethorphan/quinidine (DM...ist. The data were accepted as,late-breakers, and...
...RIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Arche...overing and developing,aptamers, announced the suc... aptamer therapeutic, ARC1779. ARC1779 is designed... aggregation of,platelets by inhibiting the bindin...tor on platelets. Activated vWF is scientifically,...
Other Medicine Technology:AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7Archemix Announces Completion of Phase 1 Trial of ARC1779 2Archemix Announces Completion of Phase 1 Trial of ARC1779 3
(Date:12/2/2008)...NDO, Fla., Dec. 2 MEDai, Inc., hea...olutions provider, has added a new module,to its ...The new stand-alone,module monitors a population,...s and alerts stakeholders when there has been a de... Navigator Guidelines(TM) provides,real-time deci...
(Date:12/2/2008)...inal Special Features MLS Stars and Promotes Healt.../ -- Juniper Content Corporation,s (OTC Bulletin ...astest-growing Spanish-language children,s network... special Juega Como un MLS Pro , the climax of th...ue Soccer, on Sunday, December 7th at 7 PM EST. ,...
(Date:12/2/2008)...cts to File NDA with FDA in Early to Mid-2009 , ... Rx, the developers of PharmFilm(R) technology and...g thin film pharmaceutical products, and Strativa ... of Par Pharmaceutical Companies, Inc. (NYSE: PR...all pivotal bioequivalence studies for a thin film...
(Date:12/2/2008)...IN, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- C...l" or "the Company") (Nasdaq: CSKI ), a leading,... over-the-counter drugs in,the People,s Republic ...(Stanley) Hao was appointed Chief Financial Office...y,s Board of Directors. He replaces Yu-kun Zhang,...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3
...dical regulatory officials have given the green si...rthritis// called Prexige which is described as a ...ffects like cardiac complications which is associa...or arthritis and of the same class .Those who have...
... used in treating cancer , in which antibodies wh... injected into patients.// These antibodies target...livering the radioactive particles . The main adva...very specific , unlike chemotherapy. A study in m...
...osis and badly treated fractures are some of the r...edlessly and are often laid up, according to ortho...ar with the world with many delicate and complicat...y," said Surya Bhan, head of the orthopaedics depa...
...he number of deaths due to alcoholism has raised t...nal Statistics (ONS) revealed that the number of d...d it has risen to 8,386 by last year. According to...nd easy accessibility are responsible for the incr...
Other Medicine News:Health News:A New Option For AIDS Treatment - Radioimmunotherapy 2Health News:Mismanagement of fractures a major concern, say experts 2Health News:Deaths due to heavy drinking has doubled in 15 years 2
Standard reading test. "Clearing weather..."
Directional `E' and `C' test.
...These Low Contrast Flip charts contain 5 pages of ...ach page. Optotype size is 9.5M. Contrast levels a... can be used at several different distances. These...a different set of symbols to guard against memor...
...The PowerLab/4SP is a high-performance data acquis... applications including human and animal physiolog..., biochemistry, and biomedical engineering. The un...fast speeds (up to 200 000 samples per second cont...
Medicine Products: